These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 1669013)

  • 41. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH; Leonhard B
    Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies.
    Cullmann W
    Zentralbl Bakteriol; 1991 Oct; 275(4):500-3. PubMed ID: 1661596
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics.
    Wu PJ; Shannon K; Phillips I
    Antimicrob Agents Chemother; 1994 Mar; 38(3):494-8. PubMed ID: 8203843
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
    Thomson CJ; Amyes SG
    J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
    Livermore DM; Yuan M
    J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions.
    Hirakata Y; Ohmori K; Mikuriya M; Saika T; Matsuzaki K; Hasegawa M; Hatta M; Yamamoto N; Kunishima H; Yano H; Kitagawa M; Arai K; Kawakami K; Kobayashi I; Jones RN; Kohno S; Yamaguchi K; Kaku M
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4225-30. PubMed ID: 19651910
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
    Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
    J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Resistance to amoxicillin and amoxicillin-clavulanic acid combination of 231 clinical strains of Escherichia coli, isolated in 1992 at the Cochin Hospital].
    Bémer-Melchior P; Gilly L; Jugroot-Klotz K; Brun T; Névot P; Paul G
    Pathol Biol (Paris); 1995 Nov; 43(9):760-5. PubMed ID: 8746097
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.
    Cormican M; Corbett-Feeney G; Kelly S; Hughes D; Flynn J; Jones RN
    Ir J Med Sci; 1998; 167(3):155-9. PubMed ID: 9780564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. beta-Lactamase types amongst Staphylococcus aureus isolates in relation to susceptibility to beta-lactamase inhibitor combinations.
    Bonfiglio G; Livermore DM
    J Antimicrob Chemother; 1994 Mar; 33(3):465-81. PubMed ID: 8040112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.
    Stapleton P; Wu PJ; King A; Shannon K; French G; Phillips I
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2478-83. PubMed ID: 8585729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria.
    Kuck NA; Petersen PJ; Weiss WJ; Testa RT
    J Chemother; 1989 Jun; 1(3):155-61. PubMed ID: 2552030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of Escherichia coli and associated β-lactamases genes from diabetic foot ulcers by multiplex PCR and molecular modeling and docking of SHV-1, TEM-1, and OXA-1 β-lactamases with clindamycin and piperacillin-tazobactam.
    Shahi SK; Singh VK; Kumar A
    PLoS One; 2013; 8(7):e68234. PubMed ID: 23861873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae.
    Cooper CE; Slocombe B; White AR
    J Antimicrob Chemother; 1990 Sep; 26(3):371-80. PubMed ID: 2121699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.